Alliance Global Partners lowered the firm’s price target on PDS Biotechnology (PDSB) to $4.50 from $7 and keeps a Buy rating on the ...

Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug from China's LaNova Medicines.Please watch the video at Investors.com - ...

Checkpoint Therapeutics' cosibelimab shows strong efficacy in treating cSCC. Learn why CKPT stock could see significant gains ...

Shares of Immutep (NASDAQ:IMMP) climbed 11% Thursday after the Australian company reported positive data from two clinical trials of its drug candidate eftilagimod alpha, or efti. Immutep (IMMP) said ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

Media Release Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and exceeding expectations: Median Overall Survival is 32.9 ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

Immutep's INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

MERCK & Co licenced an experimental cancer antibody from a closely held Chinese company in a deal worth US$588 million ...

Immutep's American depositary receipts jumped after the company reported positive data from a trial evaluating its drug Efti in combination with Merck's therapy Keytruda for treating non-small cell ...